daratumumab
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.